Chan Soon-Shiong Institute for Medicine
El Segundo, California 90245
3 studies enrolling now · 32 studies all time
What they study most
Breast Cancer, COVID-19, Cancer, Cervical Cancer, Chordoma, Clear Cell Sarcoma, Colorectal Cancer, Colorectal Cancer Metastatic, Covid19, Diffuse Large B Cell Lymphoma, Gastric Cancer, Head and Neck Squamous Cell Carcinoma
Studies at this site
- Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In — Recruiting now
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer — Recruiting now
- A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer — Recruiting now
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer — Stopped early
- QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. — Completed
- QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers — Completed
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors — Running, not enrolling
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer — Running, not enrolling
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors — Running, not enrolling
- Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis — Completed
- Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy — Available (expanded access)
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer — Withdrawn before enrolling
- QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma — Withdrawn before enrolling
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine — Withdrawn before enrolling
- QUILT-3.088: NANT Pancreatic Cancer Vaccine — Withdrawn before enrolling
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. — Withdrawn before enrolling
- QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer — Stopped early
- QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy — Stopped early
- QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine — Stopped early
- QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors — Completed
- COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA — Stopped early
- QUILT-3.080: NANT Pancreatic Cancer Vaccine — Stopped early
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. — Stopped early
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed — Stopped early
- QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy — Stopped early
- QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma — Stopped early
- QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy — Stopped early
- COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers — Completed
- A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer — Stopped early
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine — Withdrawn before enrolling
- QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas — Withdrawn before enrolling
- QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors — Withdrawn before enrolling